Tuesday, April 2, 2019
Trovagene Inc. (TROV)
Improved and updated data from AML patients.
TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- AACR Data
Presentation. The company presented data from a Phase 1b clinical trial of
onvansertib in patients with acute myeloid leukemia (AML) at the American
Association for Cancer Research (AACR) annual meeting on April 1st, 2019. The
anti-leukemic activity improved with an increased number of patients treated.
The disease control rate (DCR) rose to 89% (17/19 patients) from previous
reported rate of 83% (10/12 patients) at The American Society of
Hematology (ASH) on December 2018. - Digging Through Data. In addition to the improved DCR, the overall response
rate also increased; one patient with complete response (CR), one
incomplete blood recovery (iCR), one morphologic leukemia-freestate (MLFS) and
one partial response (PR) compar…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
